SCHEMBL5953538

SCHEMBL5953538

CC1=Cc2c(cccc2Cc2ccccc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.42
CALM1 P0DP23 1/20 0.37
BCL2 P10415 1/20 0.36
BCL2L1 Q07817 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C19 P33261 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.34
HRH1 P35367 3/20 0.34
PNMT P11086 1/20 0.34
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
DRD4 P21917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5953854 0.83 SIGMAR1 (0.39) HTR2ASMN1; SMN2CYP2D6NPSR1DRD2
SCHEMBL5953689 0.82 HTR2A (0.39) HTR2ACALM1BCL2BCL2L1SMN1; SMN2
SCHEMBL7465941 0.80 PNMT (0.35) HTR2APNMT
SCHEMBL7628272 0.78 GABRA1 (0.40) HTR2ACYP2D6MEN1KMT2APNMT
SCHEMBL5953551 0.77 HTR2A (0.36) HTR2ACALM1BCL2BCL2L1SMN1; SMN2
SCHEMBL5954058 0.75 HTR2A (0.41) HTR2ACALM1BCL2BCL2L1CYP3A4
SCHEMBL7861886 0.71 CALM1 (0.52) HTR2ACALM1BCL2BCL2L1SMN1; SMN2
SCHEMBL6905933 0.69 HTR2A (0.41) HTR2ACALM1BCL2BCL2L1SMN1; SMN2
SCHEMBL1827132 0.69 PDCD1 (0.39) BCL2L1HPGDKMT2ATSHR
SCHEMBL30229874 0.69 PDCD1 (0.39) BCL2L1HPGDKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052620-A1 Preparation of substituted indenes BASELL POLYOLEFINE GMBH (DE) 2006-03-09 US disclosed
EP-1492749-A1 PREPARATION OF SUBSTITUTED INDENES Basell Polyolefine GmbH (DE) 2005-01-05 EP disclosed
WO-2003084904-A1 PREPARATION OF SUBSTITUTED INDENES BASELL POLYOLEFINE GMBH (DE) 2003-10-16 WO disclosed
EP-1150986-A4 SILYL AMINES BOULDER SCIENT CO (US) 2002-08-07 EP disclosed
EP-1150986-A1 SILYL AMINES BOULDER SCIENTIFIC COMPANY (US) 2001-11-07 EP disclosed
WO-2001038334-A1 SILYL AMINES BOULDER SCIENTIFIC COMPANY (US) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052620-A1 Preparation of substituted indenes INTS9, CYP1A2, INF2 HTR2A 3428/4885CALM1 3779/4885BCL2 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.